HSG

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Generation Lab is a company focused on advancing human health through the development of innovative biological age testing services. By creating a test that assesses an individual's biological age progression and associated disease risks, Generation Lab aims to provide clinically applicable insights that can contribute to healthier and longer lives. The company offers clinical-grade longevity reports and health span data analysis, leveraging cutting-edge genomic research to empower healthcare professionals in optimizing patient health.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

GenAssist Therapeutics, founded in July 2020 by a team of leading scientists and industry experts, specializes in the development of gene therapy drugs utilizing advanced base editing technology. The company is focused on addressing neuromuscular diseases that currently lack effective treatments, particularly Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). GenAssist aims to provide permanent cures by precisely repairing disease-causing genes directly within patients' cells. The company holds global intellectual property rights to its proprietary Targeted AID-based Mutagenesis (TAM) technology, positioning it at the forefront of innovative solutions for a range of genetic disorders.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

Frontera Therapeutics is a company specializing in adeno-associated virus (AAV) gene therapy, dedicated to creating a low-cost and scalable platform for the development and production of high-quality recombinant AAV therapies. The company focuses on commercializing cost-effective gene therapies aimed at treating a range of genetic disorders, including those affecting ophthalmology, liver, metabolic, and neuromuscular diseases. Frontera Therapeutics has established a robust product pipeline that encompasses multiple therapeutic areas, with various candidates at different stages of development. Through its innovative approach, the company aims to improve patient outcomes by making genetic therapies more accessible and affordable in the global market.

NuProbe, Inc. is a genomics and molecular diagnostics company that specializes in noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative polymerase chain reaction (qPCR) mutation detection. The company's innovative probe technology facilitates a Sample-In Answer-Out (SIAO) solution, integrating cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations. This precision diagnostic technology is designed for the early detection of cancer and infectious diseases, offering high sensitivity and the ability to capture disease signatures comprehensively. As a result, healthcare specialists are empowered to act swiftly, enabling timely treatment for patients.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Grit Science is a biotechnology company specializing in gene therapeutics, focusing on the research and development of liver-related genetic treatments. The firm is dedicated to creating innovative medical products that address clinical needs and enhance human health. Through its commitment to advancing biopharmaceutical technology, Grit Science aims to provide effective solutions in the field of genetic medicine.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

PackGene Biotech is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) based in the United States, specializing in viral vectors for gene therapies. The company excels in developing adeno-associated virus (AAV) vectors, mRNA, plasmid DNA, and lentiviral vector solutions. PackGene Biotech offers comprehensive services from vector design and construction to AAV, lentivirus, and mRNA production. With a focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, the company provides cost-effective, reliable, and scalable production solutions for medical industry researchers.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

NuProbe, Inc. is a genomics and molecular diagnostics company that specializes in noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative polymerase chain reaction (qPCR) mutation detection. The company's innovative probe technology facilitates a Sample-In Answer-Out (SIAO) solution, integrating cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations. This precision diagnostic technology is designed for the early detection of cancer and infectious diseases, offering high sensitivity and the ability to capture disease signatures comprehensively. As a result, healthcare specialists are empowered to act swiftly, enabling timely treatment for patients.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

PackGene Biotech is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) based in the United States, specializing in viral vectors for gene therapies. The company excels in developing adeno-associated virus (AAV) vectors, mRNA, plasmid DNA, and lentiviral vector solutions. PackGene Biotech offers comprehensive services from vector design and construction to AAV, lentivirus, and mRNA production. With a focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, the company provides cost-effective, reliable, and scalable production solutions for medical industry researchers.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.

ViGeneron GmbH is a biotechnology company specializing in the development of gene therapies aimed at treating ophthalmic diseases, particularly those with significant unmet medical needs. Founded in 2017 and based in Starnberg, Germany, ViGeneron leverages two proprietary adeno-associated virus (AAV) technology platforms: the vgAAV gene therapy vector platform, which enhances transduction efficiency and allows for less invasive intravitreal treatment, and the REVeRT platform, designed to address diseases caused by mutations in large genes. The company is committed to advancing innovative therapies for retinal disorders and collaborates with leading biopharmaceutical companies to expand its impact in other disease areas. ViGeneron’s experienced team brings extensive expertise in AAV vector technology and clinical ophthalmic gene therapy programs.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

NuProbe, Inc. is a genomics and molecular diagnostics company that specializes in noninvasive nucleic acid profiling and diagnostics. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in Shanghai, China, NuProbe has developed a platform that utilizes genetic toehold probes for quantitative polymerase chain reaction (qPCR) mutation detection. The company's innovative probe technology facilitates a Sample-In Answer-Out (SIAO) solution, integrating cell-free DNA extraction, qPCR analysis, sequencing, and bioinformatic interpretations. This precision diagnostic technology is designed for the early detection of cancer and infectious diseases, offering high sensitivity and the ability to capture disease signatures comprehensively. As a result, healthcare specialists are empowered to act swiftly, enabling timely treatment for patients.

MedGenome is a company focused on advancing global health through its sequencing genomics-based diagnostics and research platform. This platform utilizes genomics technologies, bioinformatics, computing, and big data analytics to explore the genetic underpinnings of various diseases, including cancer, metabolic disorders, eye disorders, and rare diseases. MedGenome offers high-end genetic diagnostic tests across multiple categories such as immuno-oncology, infectious diseases, reproductive health, and rare diseases. By leveraging the genetic diversity of large populations, the company aims to provide valuable insights that support the healthcare industry in understanding diseases at both genetic and molecular levels.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

MedGenome is a company focused on advancing global health through its sequencing genomics-based diagnostics and research platform. This platform utilizes genomics technologies, bioinformatics, computing, and big data analytics to explore the genetic underpinnings of various diseases, including cancer, metabolic disorders, eye disorders, and rare diseases. MedGenome offers high-end genetic diagnostic tests across multiple categories such as immuno-oncology, infectious diseases, reproductive health, and rare diseases. By leveraging the genetic diversity of large populations, the company aims to provide valuable insights that support the healthcare industry in understanding diseases at both genetic and molecular levels.

Biomodal is a developer of innovative DNA sequencing tools and technology aimed at enhancing advanced medicines, diagnostics, and personalized treatments. The company's offerings are designed to seamlessly integrate with existing sequencing and computational platforms, thereby providing clients with comprehensive genetic and epigenetic methylation information from DNA libraries in a single workflow. This integration allows for a more detailed analysis of DNA, facilitating improved insights and outcomes in genetic research and medical applications.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.